{"id":"W3132559292","doi":"10.1016/j.jtho.2021.02.009","title":"Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":258,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"Merck Sharp and Dohme; Ono Pharmaceutical; PharmaMar; Shionogi; Astellas Pharma; Daiichi-Sankyo; Cancer Research UK; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Amgen; Boehringer Ingelheim; Taiho Pharmaceutical; F. Hoffmann-La Roche; Chugai Pharmaceutical; Roche; Novartis; AbbVie; Merck; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Topotecan; Second line; Oncology; Internal medicine; Phase (matter); First line; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001561439,0.0001836568,0.001101548,0.0001513829,0.00008508181,0.0000163704,0.0002134657,0.00007917306,0.0001922984],"category_scores_gemma":[0.000979495,0.0001042106,0.00007347934,0.0004318369,0.00028234,0.00008308174,0.0001348997,0.0007875119,0.000001669462],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004333774,"about_ca_system_score_gemma":0.001521536,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004088638,"about_ca_topic_score_gemma":0.001579261,"domain_scores_codex":[0.9972834,0.0006778593,0.0009611368,0.0002694122,0.0005422854,0.0002658923],"domain_scores_gemma":[0.9965735,0.001574619,0.0006216596,0.0003979636,0.0006810997,0.0001511565],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.523316,0.0164172,0.03199019,0.0001589098,0.005002263,0.01249939,0.02163609,0.000267819,0.02436025,0.00002692341,0.003938362,0.3603866],"study_design_scores_gemma":[0.1672179,0.07160321,0.6943872,0.001064008,0.0007847008,0.001927138,0.01610982,0.0001359383,0.02164434,0.0003263006,0.02446849,0.0003309374],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9826578,0.002608706,0.00001605716,0.01323113,0.0001576482,0.0007051118,0.00005726207,0.000006998792,0.0005593207],"genre_scores_gemma":[0.9968764,0.001094153,0.0009373005,0.0004121331,0.0003567357,0.000008017928,0.0000139577,0.00001849465,0.0002828092],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.662397,"threshold_uncertainty_score":0.4249584,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0525605755118861,"score_gpt":0.4658585770188332,"score_spread":0.4132980015069471,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}